insulin resistance/triglyceride

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2010/008944, filed Dec. 14, 2010, which claims benefit of Korean Patent Application No. 10-2010-0004901, filed Jan. 19, 2010. FIELD OF THE

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2009/007905, filed Dec. 29, 2009, which claims benefit of Korean Patent Application 10-2009-0022937, filed Mar. 18, 2009. TECHNICAL FIELD The

FIELD OF THE INVENTION The present invention relates to a method of treating insulin resistance, adult onset diabetes, and metabolic syndrome X and its related complications in a mammal using a therapeutic liposomal suspension, comprising predominantly phospholipids. BACKGROUND OF THE INVENTION For

FIELD OF THE INVENTION The present invention relates to the use of an indazolemethoxy-alkanoic acid to prepare a pharmaceutical composition for reducing the blood triglyceride, cholesterol and/or glucose levels. PRIOR ART Document EP-B1-0 382 276 describes a compound of formula (I): ##STR00001## in

FIELD OF THE INVENTION This invention relates to the use of ketogenic precursors to quickly produce elevated and sustained levels of ketone bodies in the blood and methods for assisting the body's transition into nutritional ketosis. Specifically, the use of a combination of medium chain

FIELD OF THE INVENTION This invention relates to the use of ketogenic precursors to quickly produce elevated and sustained levels of ketone bodies in the blood and methods for assisting the body's transition into nutritional ketosis. Specifically, the use of a combination of medium chain

PRIORITY The present application claims the benefit of Indian Provisional Patent Application No. 1853/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/051596 filed on 28 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into

This application is a National Stage Application of International Application Number PCT/BR2007/000100, filed Apr. 26, 2007; which claims priority to Brazil Patent Application No. PI0602366-5, filed Apr. 26, 2006, all of which are incorporated herein in their entirety. The present invention relates

OTHER REFERENCES Adachi, J. and G. Ioannidis (2000). "Glucocorticoid-induced osteoporosis." Drug Development Research 49: 120-134. Amin, D., R. Rutledge, et al. (1997). "RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of

OTHER REFERENCES Adachi, J. and G. Ioannidis (2000). "Glucocorticoid-induced osteoporosis." Drug Development Research 49: 120-134. Amin, D., R. Rutledge, et al. (1997). "RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of

FIELD OF INVENTION The present invention relates to the field of medicine. More particularly, the invention relates to methods, compositions and uses for prevention and/or treatment of diabetes and/or diabetes-related disorders. BACKGROUND OF INVENTION Diabetes is caused by multiple factors and is

TECHNICAL FIELD This invention relates to a composition comprising a water extract of cinnamon and a water extract of Radix Astragali. The composition enhances insulin sensitivity and/or provides an insulin-like action. BACKGROUND OF THE INVENTION Diabetes mellitus is a major public health problem.

TECHNICAL FIELD This invention relates to a composition comprising a water extract of cinnamon and a water extract of Radix Astragali. The composition enhances insulin sensitivity and/or provides an insulin-like action. BACKGROUND OF THE INVENTION Diabetes mellitus is a major public health problem.

SEQUENCE LISTING This application contains sequence data provided on a computer readable format and as a paper version. The paper version of the sequence data is identical to the computer readable format. FIELD OF THE INVENTION The invention relates to methods and compounds to treat cardometabolic

BACKGROUND Obesity is a chronic disease that has reached global epidemic proportions with over 1 billion adults being overweight (BMI 25-29.9) or obese (BMI>30). In the U.S.A. alone, the number of adults who are either overweight or obese is estimated to be over 150 million and is still on the